Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: A combined analysis of three mathematical models

The Lancet Global Health

Volumn 2, Issue 1, 2014, Pages

  Keebler, Daniel ^a   Revill, Paul ^b   Braithwaite, Scott ^c   Phillips, Andrew ^d   Blaser, Nello ^e   Borquez, Annick ^f   Cambiano, Valentina ^d   Ciaranello, Andrea ^g   Estill, Janne ^e   Gray, Richard ^h   Hill, Andrew ⁱ   Keiser, Olivia ^e   Kessler, Jason ^c   Menzies, Nicolas A ^j   Nucifora, Kimberly A ^c   Vizcaya, Luisa Salazar ^e   Walker, Simon ^b   Welte, Alex ^a   Easterbrook, Philippa ^k   Doherty, Meg ^k   Hirnschall, Gottfried ^k   Hallett, Timothy B ^f   more..

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF YORK   (United Kingdom)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF BERN   (Switzerland)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ UNIVERSITY OF LIVERPOOL   (United Kingdom)

^j HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^k WORLD HEALTH ORGANIZATION   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; BIBLIOGRAPHIC DATABASE; CD4 LYMPHOCYTE COUNT; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; DRUG MONITORING; FUNDING; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INFORMATION PROCESSING; MATHEMATICAL MODEL; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; VIRUS LOAD; WORLD HEALTH ORGANIZATION; ADULT; COST BENEFIT ANALYSIS; DISEASE MANAGEMENT; DRUG SUBSTITUTION; ECONOMICS; HEALTH CARE COST; HIV INFECTIONS; IMMUNOLOGY; THEORETICAL MODEL; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; DISEASE MANAGEMENT; DRUG SUBSTITUTION; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; MODELS, THEORETICAL; QUALITY-ADJUSTED LIFE YEARS; VIRAL LOAD;

EID: 84890849498     PISSN: None     EISSN: 2214109X     Source Type: Journal    
DOI: 10.1016/S2214-109X(13)70048-2     Document Type: Article

References (41)

1. Gilks CF, Crowley S, Ekpini R, et al. The WHO public health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006, 368:505-510.
2. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach-2010 revision 2010, WHO, World Health Organization, Geneva.
3. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach 2013, WHO, World Health Organization, Geneva.
4. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008, 371:1443-1451.
5. Phillips AN, Pillay D, Garnett G, et al. Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line regimens in resource-limited settings. AIDS 2011, 25:843-850.
6. Estill J, Aubrière C, Egger M, et al. 2012. Viral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa: a mathematical modelling analysis. AIDS 2012, 26:1403-1413.
7. Estill J, Egger M, Johnson LF, et al. Monitoring of antiretroviral therapy programmes in Malawi, South Africa and Zambia: Mathematical Modelling Study. PLoS One 2013, 8:e57611.15.
8. Braithwaite RS, Nucifora KA, Yiannoutsous CT, et al. Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives?. J Intl AIDS Soc 2011, 14:38.
9. Kimmel AD, Weinstein MC, Anglaret X, et al. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr 2010, 54:258-268.
10. Hamers RL, Sawyer AW, Tuohy M, Stevens WS, Rinke de Wit TF, Hill AM Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis. AIDS 2012, 26:1663-1672.
11. Braithwaite RS, Nucifora KA, Toohey C, et al. How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa? Submitted; AIDS (2013). In press.
12. Murray CJ, Acharya AK Understanding DALYs (disability-adjusted life years). J Health Econ 1997, 16:703-730.
13. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 2012, 380:2129-4310.
14. Acharya A, Adam T, Baltussen R Making choices in health: WHO guide to cost effectiveness analysis 2004, World Health Organization, Geneva.
15. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL Methods for the economic evaluation of health care programmes 2005, Oxford University Press, New York, USA.
16. UNAIDS Data Tables 2011 [Internet] 2011, Joint United Nations Programme on HIV/AIDS, World Health Organization, Geneva, (accessed May 15, 2013). http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2225_UNAIDS_datatables_en.pdf.
17. Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings-the case of CÔte d'Ivoire. N Engl J Med 2006, 355:1141-1153.
18. Bishai D, Colchero A, Durack DT The cost effectiveness of antiretroviral treatment strategies in resource-limited settings. AIDS 2007, 21:1333-1340.
19. Eaton JW, Menzies NA, Stover J, et al. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. Lancet Glob Health 2014, 2:e23-e34.
20. Walensky RP, Ciaranello AL, Park JE, Freedberg KA Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature. Clin Infect Dis 2010, 51:85-92.
21. Mermin J, Ekwaru JP, Were W, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial. BMJ 2011, 343:d6792.
22. Kahn JG, Marseille E, Moore D, et al. CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectivness study. BMJ 2011, 343:d6884.
23. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010, 375:123-131. DART Trial Team.
24. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. PHPT-3: A randomized clinical trial comparing CD4 vs viral load ART monitoring/switching strategies in Thailand. 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; Feb 27-March 3, 2011. Abstr 44.
25. Saag A, Westfall A, Luhanga D, et al. Cluster randomized trial of routine vs discretionary viral load monitoring among adults starting ART: Zambia. 19th Conference on Retroviruses and Opportunistic Infections; Seattle, WA, USA; March 5-8, 2012.
26. Laurent C, Kouanfack C, Laborde-Balen G, et al. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. Lancet Infect Dis 2011, 11:825-833.
27. Boyer S, March L, Kouanfack C, et al. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis. Lancet Infect Dis 2013, 13:577-586.
28. Sigaloff KCE, Hamers RL, Wallis CL, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr 2011, 58:23-31.
29. Reynolds SJ, Sendagire H, Newell K, et al. Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda. BMC Infect Dis 2012, 12:381.
30. Attia S, Egger M, Muller M, Zwahlen M, Low N Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009, 23:1397-1404.
31. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011, 365:493-505.
32. Badri M, Lawn SD, Wood R Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis 2008, 8:89.
33. Chariwarith R, Wachirakaphan C, Kotarathititum W, et al. Sensitivity and specificity of using CD4+ measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand. Intl J Infect Dis 2007, 11:413-416.
34. Keiser O, McPhail P, Boulle A, et al. Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health 2009, 14:1220-1225.
35. Kiragga AN, Castelnuovo B, Kamya MR, Moore R, Manabe YC Regional differences in predictive accuracy of WHO immunologic failure criteria. AIDS 2012, 26:768-770.
36. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008, 22:1971-1977.
37. Moore DM, Awor A, Downing R, et al. CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 49:477-484.
38. Rawizza HE, Chaplin B, Meloni ST, et al. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis 2011, 53:1283-1290.
39. Reynolds SJ, Nakigozi G, Newell K, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 2009, 23:697-700.
40. Choosing interventions that are cost-effective: cost-effectiveness thresholds 2012, World Health Organization, Geneva, (accessed April 30, 2012). http://www.who.int/choice/costs/CER_thresholds/en/index.html.
41. Walensky RP, Wood R, Ciaranello AL, et al. Scaling up the 2010 World Health Organization HIV treatment guidelines in resource-limited settings: a model-based analysis. PLoS Med 2010, 7:e1000382.